On the 21st, Moderna announced it will be releasing ‘Spikevax-2,’ its Omicron-containing bivalent booster vaccine. When released, the vaccine will be the first Omicron-specific vaccine to be released in Korea.

Modern’s mRNA vaccine, Spikevax-2 (elasomeran/imelasomeran) has been approved by the Ministry of Food and Drug Safety on the 8th for use in people aged 18 years or older as a vaccine to prevent COVID-19.

The approval was based on Phase II/III clinical trial that evaluated the efficacy of Spikevax-2 that compared Spikevax-2 with Moderna’s previous vaccine (Spikevax) in seronegative participants (participants who have never been infected with COVID-19). Results showed tha